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Summary
To address widespread media and scientific concerns over the appropriate treatment 
of TDS with Testosterone Therapy (T Therapy), the Executive Committee of the British 
Society for Sexual Medicine developed eight consensus statements, based on current 
scientific evidence to address these controversial issues. These statements were in 
no- way designed to replace the published evidence- based guidelines on the subject 
developed by various professional organisations, but to provide specific answers to 
several current controversial issues. This review examined evidence from Medline, 
EMBASE and Cochrane searches on HG, T Therapy and cardiovascular safety from 
May 2005 to May 2015, which revealed 1714 articles, with 52 clinical trials and 32 
placebo- controlled randomised controlled trials. The task force developed the follow-
ing eight key statements.
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C O N S E N S U S
UK policy statements on testosterone deficiency
Geoffrey Hackett1,2 | Michael Kirby3,4  | David Edwards5,6 | T. Hugh Jones7,8,9 |  
Jonathan Rees10,11 | Asif Muneer6,12
1  | INTRODUCTION
In response to recent controversies,1 a British Society for Sexual 
Medicine (BSSM) task force met to develop a consensus on the use 
of exogenous testosterone in men with late- onset hypogonadism 
(HG). This is a medical issue that has long been neglected and 
which carries both physiological and psychological complications. 
Recent media coverage of two high profile but flawed publications 
has confused the situation concerning the safety of testosterone 
therapy (T Therapy).2,3 In response to US pressure groups such as 
Public Citizen, a recent Food and Drug Administration publication4 
highlighted the need for well- conducted studies to clarify the risk/
benefit issues. No such concerns were expressed by the European 
Medicine Agency.5
2  | TERMINOLOGY
The committee acknowledged that current international terminology 
caused great confusion. We have attempted to use terms consistently 
to promote clarity. The US preference is for the term “T Therapy” and 
“low T” but the committee preferred to older term “T Therapy,” which 
suggests a physiological replacement following measured evidence of 
deficiency. The older term HG is still preferred by traditional urolo-
gists and endocrinologists and is often the only term accepted by tra-
ditional medical journals. The term “late- onset HG” is often used to 
describe the condition of mixed primary and secondary HG usually 
found in older men and is used in an attempt to differentiate from 
“classical” HG associated with underproduction of testosterone from 
traditional disorders of the testis (primary) or pituitary (secondary).
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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2.1 | Testosterone deficiency is a well- established, 
significant medical condition
The current International Society for Study of the Ageing Male 
(ISSAM),6 European Association of Urology (EAU),7 International 
Society for Sexual Medicine (ISSM),8 and BSSM9 definition of HG or 
Testosterone Deficiency Syndrome (TDS) is as follows: “A biochemical 
syndrome associated with advancing age and characterised by a defi-
ciency in serum androgen levels with or without a decreased genomic 
sensitivity to androgens. It may result in significant alterations in the 
quality of life and adversely affect the function of multiple organ sys-
tems” (Figure 1).10
It is worthy of note that the ISSM,8 EAU7 and ISSAM6 guidelines 
have been updated (2015), but the Endocrine Society (ES) guidelines 
date from 201011 and therefore do not reflect the vast literature of the 
amount of literature published in the last 5 years (Table 1).
The most relevant clinical symptoms/signs of HG, as per EAU and 
ISSM guidelines, are listed in Table 2.7,8
European Association of Urology, ISSM and BSSM guidelines 
suggest that a level of total testosterone (TT) of <8 nmol/L or free 
testosterone (FT) of <180 pmol/L (based on two separate 8- 11 am 
levels) requires T Therapy and TT of >12 nmol/L or FT of >225 pmol/L 
does not. Between these levels, a trial of therapy for a minimum of 
6 months should be considered based on symptoms.7 The ES in 2010 
recommended testosterone assessment in a number of high- risk 
groups, including those with type 2 diabetes mellitus (T2DM) and 
metabolic syndrome, along with chronic illnesses such as heart failure, 
renal failure, and human immunodeficiency virus (HIV), and men tak-
ing long- term opiate analgesics and anticonvulsants.11 The ES advised 
measuring testosterone for erectile dysfunction (ED) and symptomatic 
HG but stopped short of recommending screening for testosterone in 
diabetes despite a 40% prevalence.12 ED and TDS have been shown in 
studies to be independently associated with reduced quality of life.13
The European Male Aging Study (EMAS) evaluated over 3000 men 
aged 40- 7014 according to biochemistry and symptoms and showed 
that 75% of men maintain normal testosterone levels into old age, 
suggesting that HG was not merely a function of ageing. The preva-
lence of secondary HG was 11.8%, with 2% suffering primary HG and 
9.5% suffering from compensated HG worthy of observation but not 
T Therapy.
2.2 | Testosterone deficiency has well- 
established symptoms
The most prevalent symptoms of male HG in ageing men are reduced 
sexual desire and sexual activity, ED, loss of morning erections and 
hot flushes.7 Other factors found associated with low testosterone 
What’s known
There have been recent controversies on the use of exoge-
nous testosterone in men with late- onset hypogonadism. 
This is a medical issue that has long been neglected and 
which carries both physiological and psychological 
complications.
What’s new
These statements are developed for UK practice and take 
into account the outcomes from an International expert 
consensus conference on testosterone deficiency and its 
treatment held in Prague 2015. The statements have been 
developed to address widespread media and scientific con-
cerns over the appropriate treatment of TDS with T Therapy.
F IGURE  1 Effect of testosterone on multiple organ systems10
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include increased waist circumference, obesity, metabolic syndrome 
and impaired health status. Mulligan et al. reported the odds ratio for 
HG with comorbid conditions in a primary care population as hyper-
tension 1.84, dyslipidaemia 1.47, type 2 diabetes 2.09, obesity 2.38, 
LUTS/BPH 1.20 and COPD 1.40.15 Severe HG is associated with in-
creased risk of osteoporosis and chronic anaemia.
Other less- specific symptoms are loss of physical strength and 
muscle mass, fatigue, changes in mood, anger, sleep disturbance and 
cognitive impairment. Classical signs are decreased body hair, gynae-
comastia, and decreased testicular volume. Signs and symptoms of 
androgen deficiency vary depending on age of onset, duration and the 
severity of the deficiency.7 Zitzmann et al.16 reported on 434 consec-
utive hypogonadal men also reported loss of erections around TT of 
8 nmol/L, diabetes and depression at 10 nmol/L, obesity at 12 nmol/L 
and reduced vigour at 15 nmol/L. Hackett et al.17 demonstrated that 
in men with T2DM, symptoms improve in a similar fashion as testos-
terone levels improve with therapy.
The clinical response to T Therapy appears unrelated to the under-
lying aetiology,18 as recent trials have shown benefits in men without 
“classical HG,” as these text- book conditions are relatively rare in the 
general population. It is a matter of clinical judgement and patient ex-
pectation as to whether the underlying conditions should be addressed 
first, but evidence suggests that better outcomes may be achieved if 
lifestyle, appropriate medications and T Therapy are combined.19
T Therapy is appropriate to treat ED, especially in men with TT lev-
els below 8 nmol/L7–9 and to salvage ED treatment failures with oral 
medication especially at TT levels below 10.4 nmol/L.20 Appropriate 
interventions with testosterone supplementation reduce the needs for 
more invasive second- and third- line treatment.21 These indications 
for T Therapy are often vitally important to the patient but considered 
to be of low importance by the physician not specialising in sexual 
dysfunction.
2.3 | Testosterone therapy for men with 
testosterone deficiency is effective, rational, and 
evidence based
Several meta- analyses of RCTs, notably by Corona et al.,22 have con-
cluded that T Therapy in men with HG significantly improves sexual 
desire, erectile function (especially in men below 8 nmol/L), increases 
sexual activity, satisfaction and orgasm. In a meta- analysis of 59 RCTs 
involving 5078 subjects, T Therapy was found not to significantly 
change body weight, body mass index (BMI) or waistline in RCTs but 
consistently improves lean muscle and decreases fat mass.22
In February 2016, the largest long- term double- blind placebo- 
controlled study of T Therapy for HG, in 790 men over 65 years with 
12- month duration, was published.23 This showed significant improve-
ments in sexual function and modest improvement in 6- minute walk-
ing test, functional performance, mood, depression and fatigue. The 
TABLE  1 Current guidelines on hypogonadism
Organisation Recommendation TT levels Follow- up Monitoring
ISSM 20158 Symptomatic HG, ED 
and low desire
<8 nmol/L is likely to benefit 
8- 12 nmol/L, Check FT. Consider 
6- month trial of therapy if symptoms 
troublesome and continue if substantial 
benefit. Prolactin if TT below 5.2 nmol/L, 
TT>12 nmol/L unlikely to benefit
3- 6 months 
then 
annually
Baseline DRE, PSA 1.4 ng/dL, rise in 
any year or 0.4 per year velocity. 
Haematocrit 54%. Aim at T level 
above 15 nmol/L
BSSM 20109
EAU 20156 Decreased muscle mass 
or BMD Decreased 
libido or erection
<8 nmol/L or 8- 12 nmol/L check FT 
Consider 6- month trial of therapy
3- 6 months 
then 
annually
Baseline DRE, PSA 1.4ng/dl rise 
Baseline assessed 6 months after 
commencement. Haematocrit 54%. 
Aim at T level above 15 nmol/L
Endocrine 
Society 20107
Symptomatic HG with 
unequivocal low T. 
Low desire and ED. 
High- risk groups 
identified, but 
screening not 
recommended
200- 250 ng/dL=Frank hypogonadism. 
Prolactin if TT below 5.2 nmol/L
3- 6 months 
then 
annually
Baseline DRE. DRE plus PSA 
3- 6 months, PSA 1.4 nmol/L, 
haematocrit 54%. Aim at T level 
400- 700 ng/dL
ISSAM, ISA 
201511
Symptomatic HG, ED 
and low desire
<8 nmol/L, 8- 12 nmol/L, FT <225 pmol/L, 
consider 3- to 6- month trial of therapy
3- 6 months 
then 
annually
Baseline DRE. DRE plus PSA 
3- 6 months, PSA 1.4 nmol/L, 
Haematocrit 52.55%
TABLE  2 Most relevant clinical symptoms/signs of hypogonadism 7,8
Symptoms of TD Loss of libido
Absence of morning and night time erections
Erectile dysfunction
Ejaculatory dysfunction
Fatigue
Reduced well- being
Depression
Loss of concentration
Hot flushes
Reduced muscle mass and weakness
Reduced body hair
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composite benefits of these improvements are likely to translate into 
major quality of life and health economic benefit.23
Long- term registry studies of over 10 years, however, have shown 
progressive weight loss and decreased waist circumference and 
BMI.24,25 Cessation of therapy resulted in relapse and reversal of bene-
fits within 6 months, meaning that patients were advised that therapy 
is likely to be lifelong.20,26
Most RCTs of T Therapy were of relatively short duration, 6 months, 
or occasionally 12 months. T Therapy improved insulin resistance most 
marked in poorly controlled patients. There are small benefits in lipid 
metabolism but blood pressure is unaffected.17,27 These benefits are 
more pronounced when combined with lifestyle modifications.17 T 
Therapy has consistently been shown to improve bone mineral density 
in the lumbar spine without significant improvement in hip scores.28 
Lower urinary tract symptoms (LUTS) are improved by a mean of 2.2 
points in RCTs,27 and depression scores are improved in uncontrolled 
studies.29 Most RCTs were conducted over a 3- to 12- month duration 
and evidence strongly suggests that trials of T Therapy should be for a 
minimum of 6 months.17
Although HG is often associated with reduced fertility,7 T Therapy 
in younger men reduces LH and FSH levels and frequently causes in-
fertility after 6- 12 months which is reversible in 60- 70% of men within 
9- 12 months.28 Where fertility is an important issue for men with HG, 
then alternative therapy such as HCG or Clomiphene citrate (unli-
censed in men) should be considered.7
2.4 | There is no scientific basis for withholding T 
Therapy from men on the basis of age
Although it is commonly stated that testosterone declines with age, 
evidence from EMAS suggests that there is little decline in T levels 
between 40 and 75 in non- obese men.14 In fact, over 80% of men 
will maintain normal T levels into old age, suggesting that the term 
“age- related hypogonadism” is misleading. There is a fall in FT and bio-
available T secondary to the rise in SHBG with age, but primarily the 
increase in TD with age is related to increasing prevalence of obesity, 
T2DM, and chronic illness.14
Concerns over T Therapy in elderly men are based on the prema-
ture discontinuation of the Testosterone in Older Men trial 30. This 
involves 209 elderly frail men over 65 years randomised to receive 
either placebo or 100 g (twice the recommended dose at initiation of 
therapy) of topical testosterone gel, designed to assess frailty and mus-
cle strength and not powered to detect major cardiovascular events 
(MACE), was terminated early as there were 23 cardiovascular- related 
events (two deaths) in the 106 men in the testosterone group vs five 
in the placebo group, despite positive results in study end- points. The 
study involved rapid escalation up to 150 mg per day, above the man-
ufacturer’s recommended dose, and many of the events were reported 
with inadequate validation.31
The clinical and physiological responses to T Therapy, especially in-
creased muscle mass and strength, are seen in both younger and older 
men.22 These benefits may be of greater clinical and economic signifi-
cance in older men, as reduced muscle mass and lower limb strength 
are strongly related to frailty and increased rate of falls.32
Hackett et al. suggested a greater reduction in all- cause mortality 
in men over 7533 (Figure 2). The traditional view that younger men 
would see greater benefit from improvement in sexual symptoms has 
not been supported by recent studies.34
2.5. | Testosterone deficiency is associated with 
increased cardiovascular and all- cause mortality
There is increasing evidence from multiple long- term studies that HG 
is associated with increased cardiovascular and all- cause mortality. 
F IGURE  2 Trend for reduction in 
all- cause mortality in T2DM appears 
greatest in men over 7533. Mortality 
in patients categorised by: Group A = 
normal testosterone; B= low testosterone 
untreated; C = low testosteron
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A 10- year study from Western Australia involving 3690 older men 
concluded that TT and FT levels in the normal range were associated 
with decreased all- cause and cardiovascular mortality, for the first 
time suggesting that both low and high levels were associated with 
all- cause mortality and higher levels of dihydrotestosterone (DHT)- 
reduced cardiovascular risk.35 A recent Swedish study with a 14- year 
follow- up suggested a strong association between baseline testoster-
one and incident myocardial infarction (MI).36 Araujo et al. concluded 
that most studies involved issues in cohort selection and choice.37 
They concluded that a decrease of 2.1 standard deviations in TT was 
associated with a 25% increase in mortality. Haring et al. looked at 
the data in terms of several statistical models and found that even 
after strict adjustment for comorbidities, there was a consistent link 
between mortality risk and testosterone level throughout the stud-
ies without proving causation38 (Table 3). Similar conclusions were 
drawn from meta- analyses by Ruige et al.39 and most recently Corona 
et al.,40 where the focus was on cardiovascular disease as opposed to 
all- cause mortality. All conclude that there is a consistent link between 
low testosterone and cardiovascular disease incidence and mortality, 
but this did not prove a pathogenic link, but Muraleedharan et al. con-
cluded that low testosterone could be a “marker” of illness.41
Six published studies generally involving small samples have shown 
that low TT and FT are associated with coronary artery disease (CAD), 
and four have shown no association.42 Four studies have shown in-
verse associations between low TT and FT (Table 3) and the severity 
of CAD. One involved 803 men assessed by Gensini score, based on 
the location and number of stenotic coronary artery segments and de-
gree of luminal narrowing. Once again, such studies do not establish 
whether low TT or FT is a cause or a consequence of CAD.42 The vas-
cular role of testosterone was recently reviewed by Kelly and Jones.43 
The evidence that testosterone replacement in four retrospective 
studies improves survival does suggest that testosterone may have a 
beneficial effect.44–47
2.6 | The evidence does not support an increased 
cardiovascular risk associated with T Therapy
Possible mechanisms for adverse cardiovascular disease events with 
T Therapy may arise through a 6% increased rate of polycythaemia, 
related to multiple mechanisms.48 By conversion to oestradiol, there is 
direct stimulation of erythropoiesis in the bone marrow. Testosterone 
also stimulates erythropoietin synthesis in the kidney and in turn in-
creases erythropoiesis and T- induced increase of hepatic transcription 
factors with decreased hepcidin and as a consequence of increased 
iron usage.49 It has been suggested that supra- physiological levels as-
sociated with short- acting injections may exaggerate this effect27 as 
may the conversion of gels to DHT by the action of 5- alpha reductase 
in the skin.28 A full list of adverse events associated with T Therapy is 
shown in Table 4. These include polycythaemia with increase of haem-
atocrit and haemoglobin, gynaecomastia, loss of head hair, acne and 
other skin disorders, increased aggressiveness and hyper sexuality.
Increased levels of DHT may be associated with associated in-
creased thrombotic risk and fluid retention provoking hypertension and T
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heart failure.4 Studies with high- dose testosterone use in body build-
ers have shown reductions in high- density lipoprotein cholesterol,45 
whereas randomised studies of appropriate dose T Therapy have 
shown minimal adverse effect of T Therapy or even improvement.24,25
A retrospective US study of 8709 men2 with baseline TT of 
10.4 nmol/L or less undergoing coronary angiography involved fol-
low- up for a mean of 840 days. In the cohort of 7486 patients not 
receiving T Therapy, 681 died, 420 had MIs and 486 had strokes. 
Among 1223 patients receiving T Therapy, 67 died, 23 had MIs and 33 
had strokes. At first sight, these results would closely agree with the 
findings of other studies, but a complex statistical analysis (using >50 
covariates) reversed the trend and concluded that there was a greater 
risk in the T Therapy group. There were concerns that 1132 patients 
experiencing events were excluded because they were prescribed T 
Therapy after the event when surely these should have been included 
in the untreated group, increasing the events by 70%. Furthermore, 
there were no data on whether there was a correct diagnosis of TDS 
before T Therapy, none on compliance and some patients did not con-
tinue T Therapy, ‘and mean TT levels on T Therapy were at lower end 
of normal suggesting many were under treated. When challenged, the 
authors revised the number to 132, but conceded that 104 women 
had wrongly been included in the results.
Finkle et al.3 studied prescribing data in men treated with T 
Therapy, but with no data on blood results or symptoms. Non- fatal 
coronary events were the major end- point, assessed in the 12 months 
before and 3 months after therapy, even though benefits of T Therapy 
would take much longer and other studies had excluded the first 
3 months from analysis as the events would be likely to be related 
to the pre- existing condition. Most importantly, fatal cardiovascular 
events and all- cause mortality data were not collected despite the 
major impact of T Therapy in other studies being seen on mortality 
and not event numbers. Twelve- month posttreatment data were col-
lected but not presented. The event rates within the groups prior to 
treatment were strangely identical. They reported a small increase 
in non- fatal cardiac events in men commenced on T Therapy, more 
marked in those with increased risk. Overall events in the study were 
lower than predicted from comparable research. They failed to report 
deaths, failing to realise that a treatment that reduced mortality was 
likely to increase non- fatal events. The design was not prospective, 
casting doubts on the validity of retrospective assessment for the pre-
treatment 12- month period. Although widely quoted in public media, 
several design flaws and statistical analyses have discredited this 
article. A meta- analysis of 27 placebo- controlled trials of T Therapy 
lasting more than 12 weeks by Xu et al.50 concluded that T Therapy 
may increase the risk of cardiovascular- related events, whereas other 
meta- analyses did not, but most studies involved small cohorts with 
a small number of events. A further meta- analysis by Corona et al.51 
concluded that T Therapy was not associated with increased risk, and 
in certain cohorts, there was evidence of reduced events. They were 
critical of Xu et al. for their selection and inclusion of studies. Findings 
from the Basaria et al. paper heavily skewed the Xu findings, and the 
inclusion of a Scandinavian study involving an unlicensed oral formu-
lation in men with advanced liver cirrhosis suggested selection bias.51
A prospective study of 587 men with T2DM44 involved 5.8- year 
follow- up. Low testosterone was defined as TT <10.4 nmol/L. Fifty- 
eight men were treated with testosterone for 2 years or more. The 
mortality rate was 20% in the untreated group and 9.1% in the normal 
group independent of comorbidities and therapies. Mortality was 8.6% 
in the treated group. A similar retrospective US study involved 1031 
hypogonadal men, with 372 on T Therapy.45 The cumulative mortality 
was 21% in the untreated group vs 10% in the treated group, with the 
greatest effect in younger men and those with T2DM. Both articles 
were criticised for possible selection bias, but the strengths included 
reliable pretreatment diagnosis and accurate reporting of medications. 
Hackett et al.33 followed up 857 men with T2DM for 4 years following 
baseline testosterone measurement. Patients had been randomised 
to long- acting testosterone undecanoate (TU) or placebo assessment 
during a randomised controlled study. The investigators confirmed that 
low baseline TT and FT were associated with increased all- cause mor-
tality over a 4- year follow- up. They reported that T Therapy and the 
use of phosphodiesterase 5 inhibitors (PDE5Is) were independently 
associated with reduced all- cause mortality, with the greatest benefit 
from both T Therapy and PDE5Is being seen in older men.
Baillargeon et al.52 compared acute myocardial infarction rates for 
6355 men over 8 years, receiving at least one testosterone injection 
compared with a matched placebo group, and found no overall in-
crease in events. In the quartile at greatest risk, there was a significant 
reduction in events and mortality. The authors found no increased risk 
from venous thromboembolism. The same authors have shown sig-
nificant reductions in acute hospital admission in men treated with T 
Therapy compared with an untreated cohort.52
Anderson et al.53 searched electronic medical records between 
1996 and 2011 to identify 5695 men who had a low initial TT level, 
a subsequent testosterone level, and >3- year follow- up. Levels were 
TABLE  4 Adverse effects of testosterone therapy
Formulation Adverse effects
Injections i.m. Pain at injection site
Fluctuations in mood, energy and sexual 
desire
Coughing immediately after injection (POME)
Transdermal gels Potential risk of gel transfer to others in 
close contact
Skin irritation
Fluctuations in absorption
Subcutaneous pellets Frequent skin reactions at the application 
site
Oral 17- α- alkylated Hepatotoxicity
Cholestasis
Peliosis hepatis
Hepatic tumour
Marked decrease in HDL cholesterol
Other side effects include polycythaemia with increase of haematocrit and 
haemoglobin, gynaecomastia, loss of head hair, acne and other skin reac-
tions, increase of aggressiveness and hyper sexuality.
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correlated with testosterone supplement use. Primary outcomes were 
a composite of death, non- fatal MI, and stroke, MACE and death 
alone. T Therapy in men with low testosterone was associated with 
reduced MACE and death over 3 years compared with no or ineffec-
tive supplementation. This study suggested that the favourable impact 
of T Therapy was predominantly on mortality, rather than number of 
events, and benefits were associated with achieving therapeutic levels 
of testosterone, with no suggestion of increased risk with sustained 
higher serum levels. The same group53 have shown significant reduc-
tion in cardiovascular events in a cohort of hypogonadal men with an-
giographically diagnosed CAD.
Sharma et al.46 retrospectively evaluated 83,010 male veterans 
with documented low TT levels. The subjects were categorised into 
three groups: T Therapy with resulting normalisation of TT levels (group 
1); T Therapy without normalisation of TT levels (group 2); and did not 
receive T Therapy (group 3). The all- cause mortality (HR 0.53, 95% 
CI 0.50- 0.55), risk of MI (HR 0.82, 95% CI 0.71- 0.95) and stroke (HR 
0.70, 95% CI 0.51- 0.96) were significantly lower in group 1 vs group 2 
(n=25 701, median age 66 years, mean follow- up 4.6 years) (Figure 3).
These studies present the most compelling evidence to date 
for the safety of T Therapy in patients with reduction in mortality 
clearly defined HG treated to the therapeutic range, suggesting 
that studies with negative outcomes usually included inadequate 
diagnosis and little evidence of effective therapeutic levels or ade-
quate follow- up (Figure 3). Several registry studies have published 
data with over 7- year follow- up, with no suggestion of increased 
mortality.
Recent evidence suggests that responsiveness to T Therapy is de-
pendent not only on the serum testosterone concentration but also 
on the length of CAG repeats on the androgen receptor. Longer CAG 
repeats are associated with more severe symptoms and reduced re-
sponse to therapy at standard doses. The large ethnic variations in 
CAG repeats within different ethnic groups are of particularly import-
ant in the UK population.54,55
2.7 | There is no evidence that supports any increase 
in the risk of cancer of the prostate with testosterone 
replacement therapy
Guidelines of the ES, ISSM, EAU, ESSM, ISSM and BSSM all conclude 
that there is no evidence that T Therapy is associated with increased 
risk of prostate cancer.7–11 Recent studies suggest that lower levels 
F IGURE  3 Kaplan- Meier curve depicting the all- cause mortality among different propensity- matched study groups46
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of testosterone are associated with the risk of poorly differentiated 
cancers and greater risk of positive biopsy.56
There is now strong evidence linking low T concentrations to ag-
gressive, high- grade prostate cancer, higher rates of positive biopsy, 
biochemical recurrence and disease progression in men involved in 
active surveillance.57
The 2015 EAU guidelines 7 make the following statement.
T Therapy results in a marginal increase in PSA and pros-
tate volume, plateauing at 12 months. Previous fears that 
T Therapy might increase the risk of prostate cancer have 
been contradicted by a number of meta- analyses.
There are insufficient long- term data available to conclude that 
there is safety from prostate cancer with T Therapy. Prostate mon-
itoring, therefore, remains indicated. Subjects with a substantial or 
continuous increase in PSA level (taking the level 6 months7 after 
treatment initiation as baseline) need to be investigated to exclude 
prostate cancer.
2.8 | A major research initiative to explore the 
benefits of T Therapy in cardio- metabolic disease 
is overdue
Most reviews conclude that a long- term RCT is required to definitively 
answer the complex issues around T Therapy.
The Testosterone for the prevention of Diabetes Mellitus (T4DM) 
(t4dm.org.au) study in Australia58 involves younger (n=1500), obese 
men with glucose intolerance and testosterone levels of 8- 11 nmo-
l/L, randomised to long- acting TU or placebo, to establish whether T 
Therapy will reduce the development of T2DM. This might provide im-
portant answers for younger men, but will not answer questions about 
risk/benefits in older populations.
It is unlikely that definitive answers will be found to the many 
questions raised in this article without huge independent funding. 
With considerable evidence of benefit associated with T Therapy for 
HG, it is unlikely that ethical approval will be granted for sufficiently 
powered placebo- controlled studies lasting several years.
3  | CONCLUSIONS
Testosterone deficiency is a well- established, significant medical con-
dition with defined clinical symptoms and is associated with increased 
cardiovascular and all- cause mortality. Treatment is effective, evidence 
based and safe. Recent studies suggest that T Therapy resulting in 
sustained normalisation of serum levels is probably associated with 
reduced mortality. Currently available T Therapy treatment modali-
ties and their advantages and disadvantages are outlined in Table 5. 
T Therapy is associated with multiple benefits maybe highly relevant 
to the patient but underestimated by specialist physicians focused on 
specific outcomes. Until the definitive well- powered long- term study 
is published, we hope that these consensus statements will enable pa-
tients to be treated on best available evidence (Table 6).
TABLE  6 BSSM policy statements on testosterone deficiency
BSSM policy statements on testosterone deficiency
1. Testosterone deficiency is a well- established, significant medical 
condition
2. Testosterone deficiency has well- established symptoms
3. Testosterone therapy for men with testosterone deficiency is 
effective, rational and evidence based
4. There is no scientific basis for withholding testosterone therapy 
from men on the basis of age
5. Testosterone deficiency is associated with increased cardiovascular 
and all- cause mortality
6. The evidence does not support an increased cardiovascular risk 
associated with testosterone therapy
7. There is no evidence that supports any increase in the risk of 
cancer of the prostate with testosterone replacement therapy
8. A major research initiative to explore the benefits of testosterone 
therapy in cardiometabolic disease is overdue
TABLE  5 TRT treatment options7
Route of administration TRT formulation Advantages Disadvantages
Transdermal gel Transdermal testosterone Quick onset 
Steady- state testosterone levels
Skin irritation at the site of application
Risk of interpersonal transfer
Long- term patient non- compliance
Oral Testosterone undecanoate Absorbed through the lymphatic 
system (reduction of liver 
involvement)
Variable levels of testosterone
Several doses needed per day with intake of 
fatty food
Intramuscular Testosterone undecanoate Steady- state testosterone levels 
without fluctuation 
Three monthly injections improving 
patient compliance
Long- acting preparation—does not allow drug 
withdrawal in case of side effects
Testosterone enanthate/
propionate injections
Short- acting preparation that allows 
drug withdrawal in case of onset of 
side effects
Short- term—One injection every 2- 3 weeks
Fluctuation of testosterone levels
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